Herbal Monograph
Guggul
Commiphora wightii (Arn.) Bhandari
Burseraceae (Frankincense/Myrrh family)
Ayurveda's premier metabolic resin — FXR-modulating guggulsterones for lipid metabolism, anti-inflammatory joint support, and thyroid activation.
Overview
Plant Description
Small, thorny, much-branched deciduous tree or large shrub, typically 1.5-4 m tall (occasionally to 5 m). Bark is thin, papery, peeling in flakes, silvery-gray to ash-colored, exposing a smooth greenish or yellowish underbark. Branches are knotty, with sharp thorns at the nodes. Leaves are trifoliate (3 leaflets), small, 1-3 cm long, with an ovate to rhomboid terminal leaflet larger than the two lateral leaflets; leaves are shed during the long dry season (the tree is leafless for much of the year). Flowers are small, brownish-red, sessile, appearing before or with the new leaves at the beginning of the monsoon. Fruit is a small drupe, 6-8 mm, ovoid, red when ripe, with a fleshy outer layer surrounding a bony 2-valved stone. The medicinally important part is the oleo-gum-resin (guggul), which exudes from wounds or incisions in the bark as a pale yellow, viscous, aromatic sap that hardens on exposure to air into brownish, translucent to opaque, irregularly shaped tears or lumps with a balsamic, somewhat bitter, aromatic odor.
Habitat
Arid and semi-arid rocky terrain of the Thar Desert and Aravalli Hills. Grows on dry, rocky, calcareous slopes, ravines, and degraded scrublands. Extremely drought-tolerant; thrives in hot, dry climates with less than 500 mm annual rainfall and temperatures up to 45°C. Prefers well-drained rocky or sandy soils; intolerant of waterlogging. Altitude range: lowlands to approximately 800 m.
Distribution
Native to the arid regions of the Indian subcontinent, primarily Rajasthan and Gujarat states of India, extending into Pakistan (Sindh, Baluchistan) and Bangladesh. Also reported from parts of northern Africa and the Arabian Peninsula. The species is now classified as Critically Endangered by the IUCN due to overexploitation of wild populations for resin harvesting combined with its slow growth rate, poor natural regeneration, and habitat degradation. Wild populations have declined by an estimated 80% over the past century.
Parts Used
Oleo-gum-resin (guggul, guggulu)
Preferred: Purified resin (shuddha guggulu) for traditional Ayurvedic formulations; standardized extract (typically 2.5-5% guggulsterones) for modern clinical applications; crude resin for external use (fumigation, plaster)
The oleogum resin exudate is the exclusive medicinal part. It contains a complex mixture of steroids (guggulsterones), diterpenoids (myrrhanol, cembrene), essential oils, gum (polysaccharides), and resin acids. The crude resin is purified in Ayurvedic pharmacy by the process of shodhana (purification), traditionally by boiling in triphala (three-fruit) decoction, cow's milk, or cow's urine to remove impurities and reduce irritant properties. Purified guggul (shuddha guggulu) is the starting material for Ayurvedic formulations. Modern pharmaceutical preparations use standardized extracts, typically standardized to guggulsterone content (E- and Z-guggulsterone).
Key Constituents
Steroids (guggulsterones)
The guggulsterones are the primary bioactive constituents responsible for guggul's hypolipidemic, anti-inflammatory, and thyroid-stimulating actions. The FXR antagonism mechanism is the cornerstone of the modern pharmacological understanding: by blocking FXR signaling in the liver, guggulsterones increase the conversion of cholesterol to bile acids (lowering circulating cholesterol) and upregulate LDL receptors (increasing LDL clearance from blood). This FXR mechanism was characterized in the landmark paper by Urizar et al. (2002, Science) and provided molecular validation for the traditional Ayurvedic hypolipidemic indication. Additionally, guggulsterones potently inhibit NF-kB — a master inflammatory transcription factor — which underpins the anti-inflammatory action relevant to atherosclerosis, arthritis, and other inflammatory conditions. Standardized extracts are typically standardized to combined E- and Z-guggulsterone content, usually 2.5% (as in Gugulipid, the original Indian standardized product) or up to 5% in some modern extracts.
Diterpenoids
The diterpenoid fraction contributes anti-inflammatory and mild antimicrobial activity. While not the primary basis for the hypolipidemic indication, the diterpenoids (particularly myrrhanol A) may enhance the overall anti-inflammatory profile relevant to atherosclerosis and joint disease. These compounds are characteristic of the Burseraceae (myrrh/frankincense) family.
Essential oil
The essential oil fraction (1-2% of crude resin) provides the characteristic balsamic aroma of guggul and contributes mild analgesic, anti-inflammatory, and antimicrobial activity. The volatile oils are also relevant to the traditional Ayurvedic practice of dhoopana (fumigation with guggul resin), used for air purification and in respiratory conditions.
Gum and other constituents
The crude guggul resin is a complex oleo-gum-resin: approximately 30-40% resin (containing the guggulsterones and diterpenoids), 20-30% gum (polysaccharides), 1-2% essential oil, and the remainder consisting of mineral matter and impurities. The traditional purification process (shodhana) removes insoluble impurities and may alter the ratio of active constituents. The whole-resin preparations used in traditional Ayurveda deliver a broader spectrum of constituents than the standardized guggulsterone extracts used in modern practice.
Herbal Actions
Reduces inflammation
Potent anti-inflammatory activity mediated through multiple mechanisms. Z-guggulsterone inhibits NF-kB activation (the master switch for inflammatory gene expression), suppresses IkBalpha kinase activity, and inhibits STAT3 signaling. This results in reduced expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), COX-2, iNOS, and matrix metalloproteinases (MMPs). The anti-inflammatory action is relevant across multiple systems: vascular (atherosclerosis), musculoskeletal (arthritis), and metabolic (insulin resistance). The diterpenoid fraction (myrrhanol A) contributes additional anti-inflammatory activity through iNOS and COX-2 inhibition. The Ayurvedic Yogaraj Guggulu formula (guggul combined with multiple anti-inflammatory herbs) is a classical preparation for inflammatory joint disease.
[1, 4, 6]Gradually restores proper body function and increases overall health
In Ayurvedic pharmacology, guggul is classified as a premier alterative (srotoshodhana — channel-cleansing) agent. It is specifically indicated for clearing ama (metabolic toxins/waste) from dhatus (tissues) and srotas (channels). The alterative action encompasses the hypolipidemic effect (clearing excess lipids from rasa and rakta dhatus), the anti-inflammatory effect (resolving chronic inflammatory accumulation), and the thyroid-stimulating effect (rekindling metabolic fire/agni). In Western herbal terms, the alterative classification reflects the gradual normalization of metabolic function, lipid metabolism, and tissue health. Guggul is one of the most important alterative resins in the Ayurvedic materia medica.
[1, 4]Protects the liver from damage
Hepatoprotective activity demonstrated in animal models. Guggulsterones protect against chemical hepatotoxicity (carbon tetrachloride, galactosamine) in rats, reducing liver enzyme elevation and histological damage. The mechanism involves antioxidant activity (scavenging of reactive oxygen species, enhancement of endogenous antioxidant enzymes) and anti-inflammatory effects (NF-kB inhibition). The FXR modulation also influences hepatic bile acid and lipid homeostasis. Clinically relevant in the context of fatty liver disease (NAFLD), where the combination of hypolipidemic, anti-inflammatory, and hepatoprotective actions is theoretically well-suited.
[4]Prevents or slows oxidative damage to cells
Antioxidant activity attributable to the combined steroid and polyphenol fractions. Guggulsterones scavenge free radicals and enhance endogenous antioxidant enzyme activity (SOD, catalase, glutathione peroxidase) in preclinical models. The antioxidant action contributes to the hepatoprotective and anti-atherosclerotic effects.
[4]Relieves pain
Mild analgesic activity, primarily secondary to the anti-inflammatory mechanism. Relevant in the context of inflammatory joint pain, where guggul-based formulas (Yogaraj Guggulu, Kaishore Guggulu) are traditionally used. The essential oil fraction (myrcene, eugenol) may contribute additional mild analgesic effects.
[1]Kills or inhibits the growth of microorganisms
Mild antimicrobial activity attributable to the essential oil and diterpenoid fractions. In vitro activity against selected bacterial species. The traditional practice of guggul dhoopana (fumigation with burning resin) was used for air purification and is documented in Sushruta Samhita for wound management and infection prevention. Not a primary antimicrobial agent in modern practice.
[4]Therapeutic Indications
Cardiovascular System
Hyperlipidemia (elevated cholesterol and triglycerides)
The most extensively studied indication. Guggul has been used for medoroga (lipid disorders) in Ayurveda for over 2,500 years; the original reference in the Sushruta Samhita describes its use for 'coating and obstruction of channels' caused by excess medas (fat). The Indian standardized extract Gugulipid (2.5% guggulsterones) was approved in India in 1986 for hyperlipidemia based on multiple positive Indian clinical trials showing 10-25% reductions in total cholesterol and 20-30% reductions in triglycerides. However, a landmark US trial by Szapary et al. (2003) in 103 hyperlipidemic adults found that gugulipid (standardized guggul extract, 1,000 mg 3× daily providing 75 mg guggulsterones) failed to lower LDL cholesterol and actually raised LDL in some patients compared to placebo. This discrepancy between Indian and Western trials has never been fully resolved but may reflect differences in diet (vegetarian vs. Western), background statin use, genetic population differences in FXR sensitivity, or extract quality/composition variations. The molecular mechanism via FXR antagonism (Urizar et al., Science 2002) is well-established. Current evidence is mixed: guggul may be more effective in populations with certain dietary patterns and metabolic profiles.
[1, 2, 3, 4]Atherosclerosis and cardiovascular risk reduction
The anti-inflammatory, antioxidant, and potential hypolipidemic actions combine to suggest cardiovascular protective effects. Guggulsterones inhibit LDL oxidation (a key step in atherosclerotic plaque formation), reduce inflammatory markers associated with cardiovascular risk (CRP, IL-6, TNF-alpha), and may improve endothelial function. These mechanisms are well-documented in preclinical models. Clinical evidence for atherosclerosis regression or cardiovascular event reduction is lacking.
[1, 4]Endocrine System
Hypothyroidism and thyroid support
Guggulsterones have demonstrated thyroid-stimulating activity in animal models: increasing iodine uptake by the thyroid, enhancing thyroid peroxidase activity, and stimulating conversion of T4 to active T3. Tripathi et al. (1984) showed that guggul extract increased thyroid function in mice. The thyroid-stimulating effect is clinically relevant in two directions: potentially beneficial in hypothyroidism (supporting thyroid hormone production and peripheral conversion) but potentially harmful in hyperthyroidism. Some practitioners use guggul as part of thyroid-support protocols, but controlled clinical trials in hypothyroid patients are lacking.
[1, 4]Obesity and metabolic syndrome
The combination of hypolipidemic, thyroid-stimulating (metabolic rate-enhancing), and anti-inflammatory actions makes guggul theoretically suitable for metabolic syndrome and obesity. In Ayurveda, guggul is a cornerstone of medoroga (obesity) treatment. Animal studies show reductions in body weight and visceral fat with guggul extract. Clinical evidence specifically for weight loss is limited and mixed. Guggul is not a standalone weight-loss agent but may have adjunctive value within a comprehensive metabolic approach.
[4]Musculoskeletal System
Osteoarthritis and inflammatory joint disease
Traditional Ayurvedic formulas for joint disease prominently feature guggul. Yogaraj Guggulu and Kaishore Guggulu are classical polyherbal formulations prescribed for amavata (rheumatoid arthritis), sandhivata (osteoarthritis), and vatarakta (gout). The NF-kB inhibition and MMP suppression by guggulsterones directly oppose the molecular pathology of joint destruction in arthritis. Singh et al. (2003) conducted a clinical study comparing a guggul-containing formula to a conventional NSAID for osteoarthritis of the knee, finding comparable pain reduction and functional improvement. While the clinical evidence base is limited, the traditional use is extensive and the anti-inflammatory mechanism is pharmacologically coherent.
[1, 4]Skin / Integumentary
Acne vulgaris (nodulocystic acne)
Thappa and Dogra (1994) conducted a small clinical trial comparing guggul (equivalent to 25 mg guggulsterones daily) to tetracycline for nodulocystic acne over 3 months. Guggul showed comparable efficacy to tetracycline in reducing acne lesion counts, particularly in patients with oily skin. The anti-inflammatory mechanism (NF-kB inhibition) and potential effects on sebum quality provide a pharmacological rationale. The evidence is very limited (single small trial) and requires replication, but this indication is of interest as a non-antibiotic approach to inflammatory acne.
[4]Hepatobiliary System
Non-alcoholic fatty liver disease (NAFLD)
The convergence of FXR modulation (regulating hepatic lipid metabolism), hepatoprotective effects (demonstrated in animal models of chemical hepatotoxicity), hypolipidemic action, and anti-inflammatory effects makes guggul a mechanistically rational candidate for NAFLD. FXR is a central regulator of hepatic bile acid and lipid homeostasis, and guggulsterone's effects on FXR signaling directly influence the pathways dysregulated in NAFLD. Clinical studies specifically in NAFLD patients are lacking.
[3, 4]Energetics
Temperature
warm
Moisture
dry
Taste
Tissue States
damp/stagnation, cold/depression
In Ayurvedic energetics: Rasa (taste) is tikta (bitter), katu (pungent), and kashaya (astringent). Virya (potency) is ushna (heating). Vipaka (post-digestive effect) is katu (pungent). Dosha effects: primarily reduces Kapha and Vata; may aggravate Pitta in excess due to its heating quality. Gunas (qualities): laghu (light), ruksha (dry), tikshna (sharp/penetrating), vishada (clear), sukshma (subtle). The combination of heating potency with dry, penetrating, and clearing qualities makes guggul the quintessential Kapha-reducing remedy — it 'scrapes' accumulated ama and meda (fat) from the tissues and channels. This is the basis of its traditional use for medoroga (obesity/lipid disorders), granthi (tumors/nodules), and sthaulya (corpulence). In Western energetic terms, guggul is warming and drying with a specific affinity for dissolving damp, stagnant accumulations — making it specifically indicated for conditions of metabolic sluggishness, lipid accumulation, tissue congestion, and cold/damp inflammatory states. It should be used cautiously in dry, depleted, Pitta-excess constitutions where the heating, drying, and penetrating qualities could aggravate tissue dehydration, acid reflux, or inflammatory heat.
Traditional Uses
Ayurvedic medicine (classical)
- Medoroga (obesity and lipid disorders): guggul is the primary herb for 'scraping' excess meda (fat) from tissues
- Amavata (rheumatoid arthritis) and sandhivata (osteoarthritis): in Yogaraj Guggulu and Kaishore Guggulu formulas
- Vatarakta (gout): in Kaishore Guggulu
- Srotoshodhana (channel cleansing): removes ama (metabolic waste) from all seven dhatus (tissues) and their channels
- Granthi (tumors, nodules, cysts, goiter): used for non-malignant growths and swellings
- Prameha (urinary/metabolic disorders including diabetes)
- Kushtha (skin diseases): particularly in damp, oozing skin conditions
- Dhoopana (fumigation): burning guggul resin for air purification, wound healing environment, and respiratory conditions
- Gandamala (cervical lymphadenopathy/scrofula)
- Vehicle (yogavahi): guggul is considered a 'yogavahi' — a substance that enhances the delivery and potency of other herbs it is combined with, acting as a carrier/potentiator in compound formulas
"Guggul is described in the earliest Ayurvedic texts. The Sushruta Samhita (c. 600 BCE) recommends guggul for medoroga (obesity) and describes its ability to reduce 'coating and obstruction of channels' by excess fat — a remarkably prescient description of atheromatous disease. The Charaka Samhita classifies guggul as lekhaniya (scraping/reducing) and describes it for vatavyadhi (neurological/musculoskeletal Vata disorders). The classical text Bhaishajya Ratnavali contains detailed formulations of the major guggul compounds (Yogaraj Guggulu, Kaishore Guggulu, Triphala Guggulu, Punarnavadi Guggulu) each targeting specific pathological processes. Guggul's classification as yogavahi means it potentiates the herbs it carries, making it the preferred resin base for compound formulations throughout Ayurvedic pharmacy."
Unani (Greco-Arab) medicine
- Known as Muql or Muql Azraq
- Treatment of obesity and excess phlegm
- Joint pain and inflammatory conditions
- Nervous disorders
- Used as a resin in plasters for swelling and joint stiffness
"In Unani medicine, guggul (Muql) is classified as having a hot and dry temperament. It is used for phlegmatic conditions (excess Balgham/Kapha), joint diseases, and as a resolvent for swellings and tumors. The overlap between Ayurvedic and Unani indications reflects both the shared geographic origin and the genuine pharmacological overlap."
[1]
Modern integrative medicine
- Standardized extract (Gugulipid) for hyperlipidemia: approved in India as a hypolipidemic drug
- Thyroid support formulas for hypothyroidism
- Anti-inflammatory formulas for osteoarthritis and general inflammation
- Weight management protocols
- Acne treatment (non-antibiotic approach)
- Metabolic syndrome and cardiovascular risk factor management
"Guggul entered modern pharmaceutical practice through Indian research in the 1960s-80s. The Central Drug Research Institute (CDRI), Lucknow, developed Gugulipid, the standardized 2.5% guggulsterone extract that received approval as a hypolipidemic drug in India in 1986 — one of the first times a traditional Ayurvedic remedy was validated through modern pharmaceutical development and regulatory approval. This represented a landmark in the integration of traditional medicine and modern pharmacology."
Modern Research
FXR antagonism — molecular mechanism discovery
Urizar et al. (2002) identified the farnesoid X receptor (FXR) as a molecular target of guggulsterones, published in Science.
Findings: Z-guggulsterone was identified as an antagonist of the farnesoid X receptor (FXR), a nuclear hormone receptor that is a key regulator of cholesterol and bile acid metabolism in the liver. FXR antagonism by guggulsterone blocks the feedback suppression of bile acid synthesis enzyme CYP7A1, leading to increased conversion of cholesterol to bile acids (lowering serum cholesterol). FXR antagonism also upregulates hepatic LDL receptor expression, increasing LDL clearance from blood. This discovery provided the molecular mechanism for the traditional hypolipidemic use of guggul and was published in one of the world's top scientific journals.
Limitations: Molecular mechanism demonstrated in cell lines and animal models. Translation to clinical efficacy in diverse human populations has been inconsistent (see Szapary et al. 2003 below). FXR biology is complex and FXR antagonism could theoretically have adverse effects on bile acid homeostasis with long-term use.
[3]
Hyperlipidemia — negative US RCT
Szapary et al. (2003) conducted a randomized, double-blind, placebo-controlled trial of gugulipid for hypercholesterolemia in 103 adults in the United States.
Findings: In this 8-week trial, gugulipid at two doses (1,000 mg and 2,000 mg 3× daily, providing 75 and 150 mg guggulsterones daily) did NOT reduce total cholesterol, LDL cholesterol, or triglycerides compared to placebo. In fact, LDL cholesterol increased slightly (4-5%) in the gugulipid groups compared to placebo, reaching statistical significance for the standard-dose group. HDL cholesterol was not significantly affected. The study also reported a hypersensitivity rash in 10% of participants in the high-dose group. This negative result contrasted sharply with multiple positive Indian trials from the 1980s-90s and generated significant controversy.
Limitations: Western population with typical American diet (high fat, high refined carbohydrate); Indian positive trials were predominantly in populations eating a lower-fat, often vegetarian diet — the dietary context may significantly affect guggulsterone efficacy. Different genetic backgrounds with potentially different FXR polymorphisms. The extract used (Gugulipid from Sabinsa Corporation) was standardized but may differ from original CDRI Gugulipid. Background medications and lifestyle factors differ between populations.
[2]
Anti-inflammatory mechanisms — NF-kB inhibition
Shishodia and Aggarwal (2004) and subsequent studies characterized the anti-inflammatory molecular mechanisms of guggulsterones.
Findings: Z-guggulsterone potently inhibits NF-kB activation induced by multiple inflammatory stimuli (TNF-alpha, IL-1beta, LPS, PMA). The mechanism involves suppression of IkBalpha kinase activation, preventing nuclear translocation of NF-kB. Downstream effects include reduced expression of COX-2, iNOS, MMP-9, VEGF, and inflammatory cytokines. Guggulsterone also inhibits STAT3 activation (another inflammatory/oncogenic transcription factor). These effects provide a comprehensive molecular rationale for guggul's anti-inflammatory and potentially anti-tumorigenic actions.
Limitations: All data are from cell culture and animal models. The concentrations of guggulsterone achieving NF-kB inhibition in vitro may not be attainable systemically at oral therapeutic doses. Clinical anti-inflammatory efficacy has limited controlled trial support in humans.
[6]
Osteoarthritis — clinical trial of guggul-containing formula
Clinical comparison of guggul-containing Ayurvedic formulation with conventional NSAID therapy for osteoarthritis of the knee.
Findings: A guggul-based Ayurvedic formulation showed comparable efficacy to a conventional NSAID in reducing pain, stiffness, and improving functional scores in patients with knee osteoarthritis over several weeks of treatment. Both groups showed significant improvement from baseline. The guggul group had fewer GI side effects than the NSAID group.
Limitations: Polyherbal formula (not guggul alone), making it impossible to attribute effects specifically to guggul. Moderate sample size. The comparator was an active NSAID rather than placebo. The trial was conducted in India in a population that may differ from Western populations in diet, genetics, and disease characteristics.
[1]
Thyroid function — preclinical evidence
Animal studies evaluating guggul's effects on thyroid hormone production and metabolism.
Findings: Guggul extract and guggulsterone administration in rodent models increased thyroid gland iodine uptake, enhanced thyroid peroxidase activity (the enzyme that incorporates iodine into thyroid hormones), and stimulated conversion of T4 to the active T3 form in peripheral tissues. The thyroid-stimulating mechanism may involve enhanced expression of thyroid-specific genes and increased peripheral deiodinase activity.
Limitations: Animal data only. Clinical trials confirming thyroid-stimulating effects in hypothyroid human patients are lacking. The thyroid-stimulating effect, while potentially beneficial in hypothyroidism, represents a contraindication in hyperthyroidism.
[4]
Preparations & Dosage
Standardized Extract
Strength: Standardized to 2.5-10% combined E- and Z-guggulsterones. Typical product: 500 mg tablet/capsule at 2.5% = 12.5 mg guggulsterones per unit.
Commercially prepared guggul extract standardized to guggulsterone content (E- and Z-guggulsterone combined). The standard commercial product (Gugulipid) is standardized to 2.5% guggulsterones. Higher-concentration extracts (5% or 10% guggulsterones) are also available. Supplied in capsule or tablet form.
Standardized to 2.5% guggulsterones: 500 mg, 3 times daily (providing 37.5 mg total guggulsterones daily). The Indian clinical trial dose that received pharmaceutical approval was 500 mg Gugulipid (2.5%) 3× daily. Higher-dose protocols: up to 1,000-2,000 mg 3× daily (as used in the Szapary et al. trial). For 5% extracts: 250-500 mg 3× daily.
2-3 times daily with meals to reduce GI irritation.
Clinical trials used 8-24 week durations. Traditional Ayurvedic use supports longer-term administration (months) as part of comprehensive treatment protocols. Monitor lipid panel and thyroid function periodically during extended use.
Not established. Not recommended for children without qualified practitioner guidance.
The standardized extract is the basis of most modern clinical research and the form that received pharmaceutical approval in India. Quality varies significantly between manufacturers — look for products specifying both E- and Z-guggulsterone content with third-party verification. The original CDRI Gugulipid was manufactured under pharmaceutical-grade conditions; many commercial products may not match this quality. Take with food to reduce the GI irritation potential of the resin constituents.
Capsule / Powder
Strength: Purified resin, non-standardized. Guggulsterone content varies by batch but is lower per gram than standardized extracts.
Purified guggul resin (shuddha guggulu) in capsule form. The resin should have undergone traditional shodhana (purification) or equivalent modern purification to remove impurities and reduce GI irritant properties.
500-1,000 mg of purified guggul resin, 2-3 times daily with meals. Traditional Ayurvedic dose: 2-4 g of shuddha guggulu daily in divided doses.
2-3 times daily with meals.
Typically 2-4 months for metabolic conditions, then reassess.
Not established.
Whole purified resin preparations deliver the full spectrum of guggul constituents (guggulsterones, diterpenoids, essential oils, gum polysaccharides) rather than the standardized guggulsterone fraction alone. Some Ayurvedic practitioners prefer the whole resin for its broader therapeutic profile and the traditional concept that the complete resin has synergistic properties not captured by standardized extracts. The classical Ayurvedic guggulu formulations (Yogaraj, Kaishore, Triphala Guggulu) use the purified whole resin as the base.
Tincture
Strength: 1:5, 60-70% ethanol (purified resin)
Macerate purified guggul resin in 60-70% ethanol at a ratio of 1:5. The resin dissolves slowly; use gentle heat (40-50°C) or extended maceration (6-8 weeks) with regular agitation. Press and filter.
2-4 mL, 2-3 times daily.
2-3 times daily with meals.
As per clinical indications.
Not recommended.
Tincture form is not traditional in Ayurveda (where guggul is used as purified resin or in compound pills/tablets) but is used in Western herbal practice for convenient liquid dosing and combination with other tinctures. The higher alcohol concentration is needed to dissolve the resinous fraction. The gum component will not fully dissolve in alcohol — the tincture primarily extracts the resin and essential oil fractions containing the guggulsterones and diterpenoids.
[5]
Safety & Interactions
Class 2c
Not to be used with specific medications (AHPA Botanical Safety Handbook)
Contraindications
Guggul has demonstrated thyroid-stimulating activity (enhanced iodine uptake, increased T4-to-T3 conversion) in preclinical studies. In patients with hyperthyroidism, further thyroid stimulation could exacerbate symptoms (tachycardia, weight loss, anxiety, tremor) and potentially precipitate thyroid storm. This is the same class of contraindication as ashwagandha for hyperthyroidism.
Allergic/hypersensitivity reactions to guggul including skin rash have been reported in clinical trials (10% incidence at high doses in the Szapary et al. trial). Patients with known allergy to Burseraceae resins (myrrh, frankincense) may be at increased risk of cross-reactivity.
While guggul demonstrates hepatoprotective effects in preclinical models, the resin constituents undergo hepatic metabolism, and the effect of guggulsterones on CYP enzyme activity (particularly CYP3A4 induction) could alter drug metabolism and potentially stress a compromised liver. Use with caution and monitoring in liver disease.
Traditional Ayurvedic sources classify guggul as garbhashaya sankochak (uterine stimulant) and advise against use during pregnancy. The emmenagogue and uterine-stimulating properties are well-recognized in traditional Ayurvedic pharmacology. No human reproductive safety data. Avoid during pregnancy and lactation.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| CYP3A4 substrates (statins, calcium channel blockers, HIV protease inhibitors, cyclosporine, many others) (Wide range — CYP3A4 metabolized drugs) | moderate | Guggulsterones induce CYP3A4 enzyme activity, potentially accelerating the metabolism and reducing the serum levels/efficacy of drugs metabolized by CYP3A4. CYP3A4 is the most important drug-metabolizing enzyme in the human body, responsible for the metabolism of approximately 50% of all clinically used drugs. |
| Levothyroxine (Synthroid) and other thyroid hormones (Thyroid hormones) | moderate | Guggul's thyroid-stimulating activity (increased T4-to-T3 conversion, enhanced thyroid iodine uptake) may produce additive effects with exogenous thyroid hormone replacement. |
| Propranolol and other beta-blockers (Beta-adrenergic blockers) | moderate | Guggulsterones may enhance the bioavailability of propranolol (possibly through P-glycoprotein modulation), potentially increasing propranolol serum levels and effects. |
| Diltiazem and other calcium channel blockers (Calcium channel blockers) | moderate | CYP3A4 induction by guggulsterone may reduce diltiazem levels. Diltiazem is extensively metabolized by CYP3A4. |
| Anticoagulants (warfarin) and antiplatelet agents (aspirin, clopidogrel) (Anticoagulants / Antiplatelets) | minor | Guggul has demonstrated anti-platelet aggregation activity in preclinical studies. Additive anticoagulant/antiplatelet effects are theoretically possible. |
| Hormonal contraceptives (combined oral contraceptives) (Estrogen/progesterone combinations) | moderate | CYP3A4 induction by guggulsterone could accelerate metabolism of ethinyl estradiol and progesterone, potentially reducing contraceptive efficacy. |
Pregnancy & Lactation
Pregnancy
unsafe
Lactation
insufficient data
PREGNANCY: Guggul is traditionally classified as a uterine stimulant (garbhashaya sankochak) in Ayurveda and is contraindicated during pregnancy. Guggulsterones may have hormonal activity (FXR modulation, thyroid stimulation, possible estrogenic activity) that could affect pregnancy. No human reproductive safety data. Avoid during pregnancy. LACTATION: No data on excretion into breast milk. The lipophilic guggulsterones could theoretically enter breast milk. Avoid during lactation until safety data are available.
Adverse Effects
References
Monograph Sources
- [1] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Gummi Gugguli. World Health Organization, Geneva (2009)
Clinical Studies
- [2] Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, Rader DJ. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA (2003) ; 290 : 765-772 . DOI: 10.1001/jama.290.6.765 . PMID: 12915429
- [3] Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) ; 296 : 1703-1706 . DOI: 10.1126/science.1072891 . PMID: 12040550
Traditional Texts
- [4] Sarup P, Bala S, Kamboj S. Pharmacology and phytochemistry of oleo-gum resin of Commiphora wightii (Guggulu). Scientifica (2015) ; 2015 : 138039 . DOI: 10.1155/2015/138039 . PMID: 26075083
- [5] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press, Rochester, VT (2003)
- [6] Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol (2007) ; 74 : 118-130 . DOI: 10.1016/j.bcp.2007.03.026 . PMID: 17493590
Last updated: 2026-03-23 | Status: published
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.